WishBone Medical, Inc. signs licensing agreement for the Guided Growth Plate

WARSAW, Ind., Dec. 14, 2018 (GLOBE NEWSWIRE) — WishBone Medical, Inc. has been granted a global, non-exclusive license for the sale of a patented guided growth plating system in children with deformed limbs.  These 3 patents were created and designed for the gradual correction of pediatric deformities in both the upper and lower extremities.

WishBone Medical is designing and developing its own guided growth plate and instrumentation systems in sterile packed, single use, disposable kits.  This product will come in both the 2-hole and 4-hole plates systems in multiple sizes as well as options in stainless steel and titanium.  The anticipated launch will be in first quarter 2019, following FDA Clearance.

Nick Deeter, Chairman of the Board WishBone Medical, said, “We are excited to enter into this license agreement of patented technologies to develop, produce and sell our guided growth systems.  These systems will provide global access in sterile packed, single use disposable kits for children who are suffering with these pediatric deformities around the world.”  Mr. Deeter added, “With this sterile packed system, we can go into hospitals and surgery centers that have not had access to the traditional reusable systems.”

Dr. Robert von Seggern, Executive Vice President at WishBone Medical, commented, “As a dedicated pediatric orthopedic company, WishBone Medical needed this product to round out its large portfolio of orthopedic implants designed specifically for children with orthopedic issues.”

About WishBone Medical, Inc.

WishBone Medical is a global pediatric orthopedic company, committed to providing anatomically appropriate innovative implants and instruments in sterile packed, single use, disposable kits, to prevent infection, reduce overall costs for our customers and achieve the best outcomes for children around the world who are still growing.  WishBone Medical currently has 42 pediatric orthopedic product systems with operations in Warsaw, IN, Istanbul, Turkey, and Singapore.

For further information, visit www.WishBoneMedical.com or call Mary Wetzel, Chief Operating Officer, at 574-306-4006.

Global $10.66 Bn Sports Medicine Devices Market Analysis and Forecasts 2017-2018 & 2025

Dublin, Dec. 13, 2018 (GLOBE NEWSWIRE) — The “Sports Medicine Devices Market to 2025 – Global Analysis and Forecasts By Product, Application, and Geography” report has been added to ResearchAndMarkets.com’s offering.

The global sports medicine devices market is expected to reach US$ 10,662.5 Mn in 2025 from US$ 5,822.6 Mn in 2017. The market is estimated to grow with a CAGR of 7.9% from 2018-2025.

The growth of the sports medicine devices market is primarily attributed to increasing incidence of sports injuries. Moreover, the presence of large number of sports medicine associations is expected to fuel the market growth. The introduction of advanced technology in the sports medicine market is expected to offer significant growth opportunity in the sports medicine devices market during the forecast period.

The innovations of the new technologies are expected to introduce new therapies and procedures that will help to reduce time and costs and provide optimized and personalized results to continue to shape the medical device industry. Also the intelligent orthopedics in combination with traditional techniques and high-end technology will enable to change the future of industry.

The associations for the sports medicine are increasing across the countries in the world. The associations are involved in spreading the awareness about the sport medicine which is helping sports players and athletes to recover from their injuries. Some of the global groups and associations for the sports medicine are International Council of Sports Science and Physical Education (ICSSPE), International Federation of Sports Medicine (FIMS) and World Federation of Athletic Training & Therapy (WFATT).

Global sports medicine devices market, based on product was segmented as, body reconstruction and repair, body support and accessories. In 2017, body reconstruction and repair segment held the largest share by the market, by product. This is mainly attributed to the benefits offered such as, reduction in pain and improved functioning. In addition, it also amplify the body’s natural healing abilities and enhances the growth of new cartilage, ligaments and tendons.

Global sports medicine devices market, based on application was segmented knee, shoulder, ankle/foot, elbow & wrist, and others. In 2017, knee segment held the largest share of market, by application. In addition, the segment is anticipated to witness a significant growth among other applications, during the forecast period.

Some of the major primary and secondary sources for sports medicine devices included in the report are World Health Organization (WHO), Organisation for Economic Co-operation (OECD), National Research Foundation (NRF), International Diabetes Federation (IDF), Canadian Institutes of Health Research (CIHR) and others.

Key Topics Covered:

1. Introduction 
1.1 Scope Of The Study
1.2 Research Report Guidance

2. Global Sports Medicine Devices Market – Key Takeaways 

3. Global Sports Medicine Devices- Market Landscape 
3.1 Overview
3.2 Market Segmentation
3.3 Pest Analysis

4. Global Sports Medicine Devices Market – Key Market Dynamics 
4.1 Key Market Drivers
4.1.1 Increase In The Number Of Sports Medicine Associations
4.1.2 Increasing Incidences Of Sports Injuries
4.1.3 Rising Demand For Minimally Invasive Methods
4.2 Key Market Opportunities
4.2.1 Penetration Into Emerging Economies
4.2.2 Introduction Of Advanced Technologies
4.3 Future Trends
4.3.1 Prevention Through Genomics
4.4 Impact Analysis

5. Sports Medicine Devices Market – Global Analysis 
5.1 Global Sports Medicine Devices Market Revenue Forecasts And Analysis
5.2 Global Sports Medicine Devices Market, By Geography – Forecasts And Analysis
5.3 Performance Of Key Players
5.3.1 Arthrex Inc.
5.3.2 Smith And Nephew
5.4 Expert Opinions

6. Global Sports Medicine Devices Market Analysis – By Product 
6.1 Overview
6.2 Global Sports Medicine Devices Market, By Product, 2017 & 2025 (%)
6.3 Body Reconstruction And Repair Market
6.3.1 Overview
6.3.2 Global Body Reconstruction And Repair Market Revenue And Forecasts To 2025 (US$ Mn)
6.3.3 Fracture And Ligament Repair Devices Market
6.3.4 Orthobiologics Market
6.3.5 Arthroscopy Devices Market
6.3.6 Prosthetic Market
6.4 Body Support Market
6.4.1 Overview
6.4.2 Global Body Support Market Revenue And Forecasts To 2025 (US$ Mn)
6.4.3 Braces Market
6.4.4 Topical Pain Relief Market
6.4.5 Compression Clothing Market
6.4.6 Thermal Therapy Devices Market
6.4.7 Others Market
6.5 Accessories Market

7. Global Sports Medicine Devices Market Analysis – By Application 
7.1 Overview
7.2 Global Sports Medicine Devices Market, By Application, 2017 & 2025 (%)
7.3 Elbow & Wrist Market
7.4 Shoulder Market
7.5 Knee Market
7.6 Ankle/Foot Market
7.7 Others Market

8. North America Sports Medicine Devices Market Revenue And Forecasts To 2025 

9. Europe Sports Medicine Devices Market Revenue And Forecasts To 2025 

10. Asia-Pacific Sports Medicine Devices Market Revenue And Forecasts To 2025 

11. Middle East & Africa Sports Medicine Devices Market Revenue And Forecasts To 2025

12. South And Central America Sports Medicine Devices Market Revenue And Forecasts To 2025 

13. Sports Medicine Devices Market – Industry Landscape 
13.1 Overview
13.2 Growth Strategies In The Sports Medicine Devices Market, 2015-2018
13.3 Organic Growth Strategies
13.3.1 Overview
13.3.2 Product Launches
13.3.3 Expansion
13.4 Inorganic Growth Strategies
13.4.1 Overview
13.4.2 Partnership
13.4.3 Acquisitions

14. Sports Medicine Devices Market, Key Company Profiles 

  • DJO Global
  • Zimmer Biomet
  • STRYKER
  • Smith & Nephew
  • DePuy Synthes
  • Wright Medical Group N.V.
  • Arthrex, Inc.
  • CONMED Corporation
  • Mueller Sports Medicine, Inc.
  • RTI Surgical, Inc.

For more information about this report visit https://www.researchandmarkets.com/research/7q4x59/global_10_66_bn?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Sports Medicine and Physiotherapy

OrthoPediatrics Corp. Announces Full-Scale U.S. Launch of Small Stature Scoliosis System

WARSAW, Ind., Dec. 13, 2018 (GLOBE NEWSWIRE) — OrthoPediatrics Corp. (NASDAQ: KIDS), a company exclusively focused on advancing the field of pediatric orthopedics, announced today the full-scale U.S. launch of its 26th surgical system, the RESPONSE 4.5/5.0mm System following U.S. Food and Drug Administration (FDA) 510(k) clearance in October. The Company’s newest system represents a significant product expansion for physicians to treat complex scoliosis in smaller stature patients at a younger age.

The RESPONSE 4.5/5.0mm System, designed in collaboration with pediatric orthopedic surgeons, builds upon the successful implant and instrument technology of the RESPONSE 5.5/6.0mm System to expand the platform offering. The new small stature scoliosis system offers a hybrid implant technology allowing the option of either a 4.5mm rod in cobalt-chromium or 5.0mm rod in titanium or cobalt-chromium, multiple implant connector options, and innovative, new instrumentation.

Dr. Jonathan Phillips, Pediatric Orthopedic Surgeon & Associate Professor of Orthopedics at University of Central Florida, College of Medicine, served as a design surgeon for the small stature system and commented, “I am excited for the launch of the highly anticipated small stature RESPONSE system from the leader in children’s orthopedic technologies. Conceived to mesh seamlessly with the exceptionally successful RESPONSE system for larger statures, this instrumentation has been designed to serve a unique weight and size demographic in children’s orthopedics and extends the versatility of OrthoPediatrics’ spinal instrumentation options. I look forward to this radical improvement to care for a diverse cohort of the most underserved children.”

RESPONSE™ Spine System
Designed with a complete focus on children, the RESPONSE system offers a simple, technologically advanced system of instruments and implants to treat the distinct needs of pediatric patients with spinal deformities. The system features advanced instrument & implant technology including 1) innovative, low profile screw design including a proprietary set screw thread design for improved fixation and reduced potential for cross threading, and 2) unique pedicle screw head accepts multiple rod diameters in either cobalt chrome or titanium. Additionally, the system has versatile reduction & de-rotation capabilities with rod reducer instrument designed for easy snap on and off 2-in-1 rod reduction instrument enables each surgeon to perform reduction and de-rotation technique of choice and serves as a rod reducer and de-rotator in one.

About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on providing a comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 26 surgical systems that serve three of the largest categories within the pediatric orthopedic market. This offering spans trauma & deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and 38 countries outside the United States.

Investor Contacts
The Ruth Group
Tram Bui / Emma Poalillo
(646) 536-7035 / 7024
tbui@theruthgroup.com / epoalillo@theruthgroup.com

Overland Park Surgical Suites First Outpatient Surgery Center In Region To Offer Robotics-Assisted Partial And Total Knee Replacement Surgery Using The NAVIO™ Surgical System

OVERLAND PARK, Kan.Dec 13, 2018 /PRNewswire/ — Overland Park Surgical Suites is a state of the art outpatient surgical center and is the first outpatient surgery center in the Midwest to offer patients a robotics-assisted alternative to traditional knee replacement surgery.

“We were eager to bring the NAVIO robotics-assisted surgery to the area,” said Scott Abraham, M.D., Orthopedic Surgeon and founder of Overland Park Surgical Suites, LLC. “This exacting technique is the preferred approach for most patients and we’ve seen dramatic surgical outcomes.”

The NAVIO Surgical System starts with an advanced computer system that gathers precise anatomic and alignment information about a damaged knee that a surgeon uses to create a specific surgical plan, according to Dr. Abraham.

“This extra layer of data collection is designed to ensure the knee procedure is performed as accurately as possible for the best long-term outcome,” he said.

Abraham has already performed more than 100 robotic-assisted partial and total knee replacements at Overland Park Surgical Suites and St. Joseph Medical Center, and draws patients to his practice from throughout KansasMissouri and Iowa. He said the NAVIO System is particularly well suited for active adults in their 40s and 50s who have developed knee problems, but have opted to put off surgery as a remedy.

“Knee replacement surgery has a controversial reputation,” Abraham added.

Unfortunately, this leads many patients to delay medical intervention because of concerns about invasive surgery, painful rehab and significant downtime. The NAVIO System helps offset these concerns with the improved accuracy and the potential for faster recovery, leading to the goal of improved surgical outcomes and increased patient satisfaction.

The first knee implant procedure was performed 50 years ago in 1968, according to the American Academy of Orthopaedic Surgeons. Now, more than 600,000 knee replacement surgeries are performed each year, making it one of the most in-demand surgical specialties in the country. Yet often, patients are dissatisfied with the outcome.

Not so for Beth Archer of Leawood, who in October was the first person in the state of Kansas to undergo a partial knee replacement using robotic surgical assistance at Overland Park Surgical Suites.

“I’d been living with knee pain for four years,” Archer said. “The quality of my life dramatically improved with my partial knee replacement done with the NAVIO Surgical System. I returned home immediately and was self-sufficient, had little pain and within a week I was walking without a cane or walker. I highly recommend this robotic surgery.”

Abraham added that the NAVIO benefits are many, yet robotic surgical-assist is still in its infancy.

“We’re proud that Overland Park Surgical Suites is the first outpatient surgery center in the region to offer this state of the art NAVIO knee replacement procedure,” Abraham said. “But we won’t be the last. In fact, we think this is the future of the surgical field. It puts the power of robotics in the skilled hand of the surgeon. And that means a better outcome for all our patients.”

For more information or to schedule a NAVIO consultation with Dr. Abraham, call APEX ORTHOPEDICS and Sports Medicine at 913-642-0200.

NOTE: Not all patients are candidates for surgery using the NAVIO Surgical System. Discuss your condition and implant options with your surgeon. Individual results of joint replacement vary. Implants may not produce the same feel or function as your original knee. There are potential risks with knee replacement surgery such as loosening, fracture, dislocation, wear and infection that may result in the need for additional surgery. NAVIO is not for everyone. Children, pregnant women, patients who have mental or neuromuscular disorders that do not allow control of the knee joint, and morbidly obese patients should not undergo a NAVIO procedure.

(www.OverlandParkSS.com
Overland Park Surgical Suites is a state-of-the-art, orthopedic outpatient surgical center in Overland Park, KS. It was established by clinical personnel to offer safe, high quality surgical care. It is one of the first surgery centers in the Kansas City area to perform outpatient total joint replacements and is licensed by the State of Kansas and accredited by The Joint Commission.

About Smith & Nephew: 
(www.RediscoverYourGo.com
Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people’s lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has around 15,000 employees and a presence in more than 100 countries. Annual sales in 2017 were more than $4.8 billion. Smith & Nephew is a member of the FTSE100.

TM is a Trademark of Smith & Nephew

Contact:      

Betsy Donnelly

Phone:         

913 208 5400

Email:           

Betsy@TrailheadMarketingTeam.com

SOURCE Overland Park Surgical Suites

Related Links

http://www.overlandparkss.com

Zimmer Biomet Announces Quarterly Dividend for Fourth Quarter of 2018

WARSAW, Ind.Dec. 12, 2018 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the fourth quarter of 2018.

The cash dividend of $0.24 per share is payable on January 31, 2019 to stockholders of record as of the close of business on December 28, 2018.

About the Company

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; office based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.

We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.

ZBH-Fin

SOURCE Zimmer Biomet Holdings, Inc.

Related Links

http://www.zimmerbiomet.com

EDGe Surgical Secures $4 Million in Series A Financing

December 12, 2018

CHICAGO–(BUSINESS WIRE)–EDGe Surgical, Inc., a privately held medical device company dedicated to innovative precision measurement solutions for orthopedic surgery, announced today that it has completed $4 million in financing. The Series A round includes $3 million raised plus a convertible note, bringing total funding secured by the company to $5.7 million, all from angel investors. Proceeds will be used for increased manufacturing, marketing and sales surrounding the company’s first device, the EDG® Ortho 65mm, as well as development and launch of a second device focused on the spinal surgery market.

The EDG Ortho 65mm is the first and only single-use electronic depth gauge. It is designed to more accurately measure length for orthopedic surgical screws, and also mitigate bioburden contamination, a leading cause of surgical site infections. EDGe Surgical’s device provides healthcare professionals, hospitals, and outpatient medical facilities with a digital alternative to analog depth gauges for greater accuracy at a decreased cost, all while mitigating infection risk.

“The positive reception we’ve received from surgeons to our pilot launch, which started earlier this year, illustrates that our device fills a major market need for a depth gauge that enables more accurate screw selection without the worry of bioburden contamination risk,” said Christopher Wilson, president and CEO of EDGe Surgical. “We appreciate the continued support of our sophisticated angel investors, who bring surgical and medical device C-suite expertise, to help us quickly move the needle. Closing our Series A round will allow us to expand availability of our EDG Ortho 65mm and develop additional new products to serve customers seeking cost-effective and highly advanced solutions.”

Until now, the most common approach for orthopedic surgical measurement has been using a traditional analog depth gauge with a sliding metal scale to determine drill depths and screw lengths. The EDG Ortho 65mm can overcome the drawbacks of these traditional depth gauges, invented almost a century ago, by eliminating many of the inefficiencies and financial costs, such as:

  • Up to 20 percent of measurements using the traditional analog depth gauge are inaccurate. Mismeasurement is a leading cause for wasted screws/implants, which is estimated at a $200 million a year cost to the healthcare system.
  • Traditional analog depth gauges are reusable by design and are difficult if not impossible to clean properly, and sterilization is not effective on insufficiently cleaned surgical instruments based on a recent study at a university hospital Level 1 trauma center.
  • Per case costs associated with using a traditional depth gauge are estimated to be greater than $400, with traditional device downsides including bone non-unions, implant-related complications, infection risk, and unnecessary radiation exposure.

The EDG Ortho 65mm can significantly reduce costs as a result of greater accuracy (i.e., less wasted screws), reduced infection risk, and greater measurement consistency. For example, the EDG Ortho 65mm reduced measurement error by up to 90 percent in recent cadaver and sawbones accuracy labs, and a study presented at the 2018 Annual Meeting of the American Society for Surgery of the Hand (ASSH) found a significant reduction in the rate of major measurement error in sawbones models compared to the traditional analog depth gauge.

For more information on EDGe Surgical and its products, visit www.edgesurgical.com and follow the company on TwitterLinkedInand YouTube.

About EDGe Surgical, Inc.

EDGe Surgical is a privately held medical device company that is innovating state-of-the-art digital technology to set a new standard in orthopedic surgery instrumentation that is bringing better outcomes to patients and reducing healthcare system costs. Founded in 2015, EDGe is focused on developing and delivering products that deliver precision to healthcare professionals specializing in orthopedic trauma and spine surgery – a potential $1.1 billion U.S. market. Located in Chicago, Illinois, EDGe is a proud member of MATTER and an active company within the iBIO Institute PROPEL Center.

Contacts

MEDIA CONTACT:
Jim Hughes
Merryman Communications
jim@merrymancommunications.com
323-397-7077

Reston Hospital Center is First in the Nation to Acquire a Second Mazor X System for Rapidly Expanding Spine Program

Reston, Virginia, Dec. 12, 2018 (GLOBE NEWSWIRE) — The Virginia Institute of Robotic Surgery at Reston Hospital Center has acquired a second Mazor X System for their rapidly growing spine program, making it the first in the nation to have two of these robotic systems at one hospital location.

The Reston Hospital Center (RHC) Spine Team is comprised of nationally-recognized spine surgeons who excel in implementing the latest in surgical advancements for spinal procedures. One of the first in the country to acquire and use Mazor Technology in 2012, RHC, in collaboration with its surgeons, has been a pioneer in using advanced technology and procedures in the operating room.  In 2016, the facility was the first in the Mid-Atlantic to acquire and perform a procedure using the latest Mazor X platform. More than 1,500 spine surgeries are performed annually at RHC, with over 600 of these procedures utilizing the advanced technology of the Mazor X system, offering patients an advanced, minimally invasive surgical option for the spine.

“Providing our surgeons with the technology and resources they need to keep our surgical program at the forefront of innovation means that our patients receive the most advanced care in the safest environment,” said John Deardorff, CEO of Reston Hospital Center and President of HCA’s Northern Virginia Market. “As a leader in spine surgery we are committed to delivering exceptional care and the best possible outcomes for our patients.”

Reston Hospital Center is one of only eight Visiting Clinician Programs (VCP) in the United States where surgeons from around the world come to train on the latest in Mazor technology.  The VCP gives surgeons the opportunity to learn about the latest in robotic-assisted spine surgery capabilities from the proctoring surgeon, Dr. Christopher Good of the Virginia Spine Institute. In addition to the surgical training, surgeons also learn how a comprehensive robotic surgical program runs from an operational and administrative perspective.

About Reston Hospital Center

Part of HCA Virginia Health System, Reston Hospital Center is a 197-bed, acute-care medical and surgical facility that has garnered high honors for attentive patient care and nursing excellence.  Reston Hospital Center is home to the region’s newest Level II Trauma Center and the most comprehensive robotic surgery in the Mid-Atlantic. Statewide, HCA Virginia Health System operates 14 hospitals and more than 30 outpatient centers and is affiliated with 3,000 physicians. It is Virginia’s fourthlargest private employer, provides $190.8 million in charity and uncompensated care, and pays $72.6 million in taxes annually. For more information about Reston Hospital Center visit www.restonhospital.com

Erin Echelmeyer
Reston Hospital Center
703-689-9030
Erin.Echelmeyer@hcahealthcare.com

Ortho RTi’s Data selected for Podium Presentation at International Conference

KIRKLAND, QCDec. 12, 2018 /PRNewswire/ – Ortho Regenerative Technologies Inc. (CSE: ORTH) (“Ortho RTi” or the “Corporation”), an emerging Orthopaedic and Sports Medicine technology company, announced that its recently completed study has been chosen by a peer reviewed panel as worthy of a podium presentation at the 2019 ICORS (International Combined meeting of Orthopaedic Research Societies) congress in June. ICORS attracts Orthopaedic surgeons, sports medicine specialists, physicians and research scientists from around the globe and is focused on how new discoveries translate into improved clinical care. The podium presentation will  feature the study titled  “Freeze-dried chitosan solubilized in platelet-rich plasma in a sheep model of rotator cuff repair”.

“Our scientific evidence continues to excel and gather the attention of world experts. This will be our 16th peer-reviewed abstract, poster, manuscript and now podium presentation in the last two years. Further, this is another key publication resulting from work with experts at New York City’s renowned Hospital for Special Surgery,” said Ortho RTi’s Chief Scientific Officer, Dr. Michael Buschmann.

Business Update

Over the last weeks our business and exposure has continued to progress significantly.

  • Last Friday we submitted our formal Pre-Submission package to the FDA seeking guidance after our recent data showed statistically significant results in as little as 3 months. The package included data from all of our studies and highlighted that Ortho-R has shown structural improvements at 6 months and as a second clinical benefit has showed improved speed of healing as evidenced by our 3-month data.
  • Over the same time period our Intellectual Property assets continued to grow with progress on multiple patent files as well as another European patent issuing in Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Netherlands, Norway, Spain, Sweden, Switzerland & Liechtenstein and the United Kingdom.
  • As part of the evolving scientific validation of our technology, a recent manuscript was selected for publication in an upcoming issue of the Journal of Biomaterials which is expected to be published in the first months of 2019.
  • Finally, our technology transfer to production and scale-up has progressed through a critical milestone with our first finished product lots in the process of being completed.

“The combination of these initiatives have also allowed us to make strong progress with strategic partners and our goals of assessing and co-developing our product for other potential clinical uses” said Dr. Brent Norton, CEO of the company.”

About the ICORS

The International Combined Orthopaedic Research Societies (ICORS) serves as an alliance of societies to promote basic, translational, and clinical musculoskeletal research worldwide. The Combined Meeting was launched in 1992 by founding member societies; Orthopaedic Research Society, Canadian Orthopaedic Research Society, European Orthopaedic Research Society, and the Japanese Orthopaedic Association.  The meeting has convened every three years since 1992 and rotated to the different country organizations. For 2019 the ICORS annual meeting is being held in Montreal, Quebec, in conjunction with the Canadian Orthopaedic Research Society and the Canadian Orthopaedic Association annual meetings.

About Rotator Cuff Injury

The rotator cuff is the name given to the collection of four tendons that stabilize the shoulder joint. The tendons around the joint can suffer tears as a result of injury to the tendon or as a result of degeneration over time. Repetitive overhead activity is often associated with cuff tears. Symptoms include a dull, aching pain, and patients often suffer secondary symptoms including lack of sleep and weakness in the arms resulting from a lack of exercise. If conservative therapy is not successful, surgery will often be performed. The principal aim of surgical intervention is to reattach the torn tendon to the bone. The standard of care involves the use of suture anchors placed into the bone and the tendon then being held in place with sutures.

About Ortho Regenerative Technologies Inc.

Ortho RTi is an emerging Orthopaedic and Sports Medicine technology company dedicated to the development of novel therapeutic soft tissue repair technologies to dramatically improve the success rate of sports medicine surgeries. Our proprietary biopolymer has been specifically designed to increase the healing rates of sports related injuries to ligaments, tendons and cartilage. The polymer can be directly placed into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention. Further information about Ortho RTi is available on the Company’s website at www.orthorti.com and on SEDAR at www.sedar.com.

Forward-Looking Statements

This news release may contain certain forward-looking statements regarding the Corporation’s expectations for future events. Such expectations are based on certain assumptions that are founded on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Corporation disclaims any intention or obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws.

SOURCE Ortho Regenerative Technologies Inc.

Related Links

http://www.orthorti.com/

Appeals Court OKs $248m Stryker win over Zimmer Biomet

 / BY 

The U.S. Court of Appeals for the Federal Circuit this week affirmed Stryker‘s (NYSE:SYK) enhanced $248 million win in a surgical tool patent case against Zimmer Biomet (NYSE:ZBH).

The Federal Circuit court affirmed the judgement in a per curiam ruling dated on Monday, according to recently released court documents.

The damages in the case were previously enhanced due to a US Supreme Court ruling which made it easier to award enhanced damages. In July, Western District of Michigan Judge Robert Jonker reaffirmed an earlier decision to award enhanced damages “in light of the Supreme Court’s clarification of the governing standard in Halo Electronics, Inc. v. Pulse Electronics, Inc.,” according to court documents.

The court was also asked to reconsider its award of attorney’s fees, due to a Supreme Court ruling in Octane Fitness, LLC, v. Icon Health & Fitness, Inc., which it also reaffirmed.

Judge Jonker reaffirmed both decisions for triple damages for the 2013 jury verdict, which had been vacated on appeal by the Federal Circuit last year. He ruled that in the case, Stryker had “proven by clear and convincing evidence” that Zimmer had willfully infringed on 1 or more claims in all 3 of the patents-in-suit, according to court documents.

 

READ THE REST HERE

 

Anika to Showcase HYALOFAST at the International Cartilage Regeneration and Joint Preservation Society (ICRS) Focus Meeting in Milan

December 12, 2018

BEDFORD, Mass.–(BUSINESS WIRE)–Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced plans to showcase its entire Orthobiologics franchise, including HYALOFAST, at the upcoming ICRS Focus Meeting in Milan, Italy at the Humanitas Research University. The ICRS is the main forum for international collaboration in cartilaginous tissue research and joint preservation, with 1300 active members from 65 countries.

HYALOFAST is a non-woven, single-step, off-the-shelf, biodegradable HA-based scaffold for hyaline-like cartilage regeneration to treat cartilage injuries and defects. HYALOFAST is commercially available in approximately 15 countries and has been used to successfully treat more than 15,000 patients internationally, and with strong eight-year patient follow-up data. HYALOFAST is pending regulatory submission in the United States and its FastTRACK Phase III trial is currently enrolling patients across the U.S. and Europe.

“The ICRS Focus Meeting in Milan is an excellent venue to further showcase the significant advantages of our entire Orthobiologics franchise before a collection of world-renowned experts in the field of cartilage repair and regeneration,” said Joseph Darling, President and CEO, Anika Therapeutics. “We believe that continuing this peer-to-peer dialogue and technical training is central to further advancing the HYALOFAST Phase III clinical trial, as well as increasing commercial adoption. HYALOFAST is a truly remarkable advancement in the treatment of cartilage injuries and defects due to its flexible minimally-invasive means of application and adaptive fit to individual patient needs.”

HYALOFAST will be featured at the International Cartilage Regeneration and Joint Preservation Society (ICRS) Focus Meeting in Milan, Italy during a technical session. The meeting, which will be attended by many of the world’s leading cartilage specialists, will showcase HYALOFAST as part of its “RE-LIVE SURGERY SESSIONS” and its clinical data program.

HYALOFAST Technical Session
Title: “Scaffolds: How to do It. Re-live Surgery and Relevant Results”
Presenter: Dr. Alberto Gobbi, OASI Bioresearch Foundation, Milano – Italy
Date/Time: December 14, 2018 at 9:30 – 10:15am

Company-Sponsored Booth
Anika will be a Gold Sponsor and will host a booth (#12) featuring guest physicians leading guided, hands-on demonstrations of HYALOFAST procedures using the HYALOFAST Arthroscopic Virtual Surgery Simulator. The company will also host “watch & try” sessions at the Anika booth.

About ICRS
The ICRS (International Cartilage Regeneration and Preservation Society) is the main forum for international collaboration in cartilaginous tissue research that brings together basic scientists, clinical researchers, physicians and members of industry, engaged or interested in the field of articular biology, its genetic basis and regenerative medicine. It provides continuing education and training to physicians and scientists with an active interest in the prevention and treatment of joint disease to improve patient care through regenerative medicine approaches.

2018 HYALOFAST Publications

1.

Gobbi A., et al. Use of bone marrow aspirate concentrate combined with hyaluronan-based scaffold for early osteoarthritis in athletes. Football Medicine Outcomes Abstract book XXVII Isokinetic Medical Group International Conference – Camp Nou, Barcelona 2-4 June 2018. Ed Calzetti & Mariucci. Page 442.

2.

Sofu H. et al. Clinical and radiographic outcomes of chitosan-glycerol phosphate/blood implant are similar with hyaluronic acid-based cell-free scaffold in the treatment of focal osteochondral lesions of the knee joint. Knee Surg Sports Traumatol Arthrosc. 2018 Aug 1. (Epub ahead of print).

3.

Gollwitzer H. Operative Therapie – Knorpelschäden der Hϋfte Einzeitiges arthroskopisches Verfahren zur Regeneration. Sportärztezeitung 03/2018 (Cartilage Damage to the Hip. One-Stage Arthroscopic Method of Regeneration).

About Anika Therapeutics, Inc.
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative tissue repair. The Company has over two decades of global expertise developing, manufacturing, and commercializing more than 20 products based on its proprietary hyaluronic acid (HA) technology. Anika’s orthopedic medicine portfolio includes ORTHOVISC®MONOVISC®, and CINGAL®, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. For more information about Anika, please visit www.anikatherapeutics.com.

Contacts

For Investor Inquiries:
Anika Therapeutics, Inc.
Sylvia Cheung, 781-457-9000
Chief Financial Officer

For Media Inquiries:
W2O Group
Sonal Vasudev, 917-523-1418 sonal@w2ogroup.com